JRC-I-191
JRC-I-191 is an anti-HIV-1 agent. JRC-I-191 inhibits HIV-1 YU-2 entry into cells. JRC-I-191 does not inhibit infection of cells by amphotropic murine leukemia virus. JRC-I-191 can be used for the research of HIV-1 infection.
For research use only. We do not sell to patients.
- CAS No.: 1098209-30-3
- Formula: C17H23ClFN3O2
- Molecular Weight:355.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
HIV-1 |
In Vitro
JRC-I-191 (Compound 3) inhibits HIV-1 YU-2 entry into Cf2Th-CD4/CCR5 cells with an IC50 of 54.4 μM, does not inhibit A-MLV infection[1].
JRC-I-191 binds to HIV-1 YU2 gp120 with a Kd of 0.76 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1098209-30-3
-
Molecular Weight 355.83
-
Formula C17H23ClFN3O2
-
SMILES
O=C(C(NC1CC(C)(C)NC(C)(C1)C)=O)NC2=CC=C(C(F)=C2)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JRC-I-191 Related Classifications
HY-182376 Related Classifications
Powered by Bioz